Skip to main content
SpringerLink
Log in

Screening for hemochromatosis: Patients with liver disease, families, and populations

  • Published:
Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Hereditary hemochromatosis is a common autosomal-recessive disorder of iron overload usually occurring in individuals who are homozygous for a C282Y mutation in the hemochromatosis (HFE) gene. Current screening methods can detect affected individuals early in disease pathogenesis, enabling early institution of effective treatment that can restore normal life expectancy. Phenotypic screening of adults using transferrin saturation and serum ferritin levels identifies the majority of individuals who develop iron overload. HFE genotyping, when combined with serum biochemical measurements, has reduced reliance on liver biopsy as a diagnostic tool and is the preferred initial screening modality for families with an affected individual. Genetic testing has altered previously held views regarding the high level of penetrance of the disease. Although the majority of C282Y homozygotes develop increased body iron stores, end-organ damage occurs much less frequently than previously thought. Screening is recommended in highrisk groups and in those with a high index of clinical suspicion. Opportunistic screening during routine health assessments may also be recommended. However, large-scale screening of the average-risk population is not recommended on the basis of current evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Olynyk JK, Bacon BR: Hereditary haemochromatosis: detecting and correcting iron overload. Postgrad Med 1994, 96:151–156.

    PubMed  CAS  Google Scholar 

  2. Simon M, Bourel M, Fauchet R, et al.: Idiopathic haemochromatosis: demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977, 297:1017–1021.

    Article  PubMed  CAS  Google Scholar 

  3. Feder JN, Gnirke A, Thomas W, et al.: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996,13:399–409.

    Article  Google Scholar 

  4. Olynyk JK: Hereditary haemochromatosis: diagnosis and management in the gene era. Liver 1999, 19:73–80.

    Article  PubMed  CAS  Google Scholar 

  5. Bomford A: Genetics of hemochromatosis. Lancet 2002,360:1673–1681. This paper offers a comprehensive review of the genes mutated in hereditary hemochromatosis, prevalence of HFE mutations, and penetrance of the disease.

    Article  Google Scholar 

  6. Roetto A, Papanikolaou G, Politou M, et al.: Mutant antimicrobial peptide is associated with severe juvenile hemochromatosis. Nat Genet 2003, 33:21–22.

    Article  PubMed  CAS  Google Scholar 

  7. Trinder D, Fox C, Vautier G, et al.: Molecular pathogenesis of iron overload. Gut 2002,51:290–295.

    Article  Google Scholar 

  8. Kato J, Fujikawa K, Kanda M, et al.: A mutation in the ironresponsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001, 69:191–197.

    Article  PubMed  CAS  Google Scholar 

  9. Bulaj ZJ, Ajioka RS, Phillips JD, et al.: Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000, 343:1529–1535.

    Article  PubMed  CAS  Google Scholar 

  10. Willis G, Wimperis JZ, Lonsdale R, et al.: Incidence of liver disease in people with HFE mutations. Gut 2000, 46:401–404.

    Article  PubMed  CAS  Google Scholar 

  11. Gochee PA, Powell LW, Cullen DJ, et al.: A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 2002, 122:646–651.

    Article  PubMed  CAS  Google Scholar 

  12. Bacon BR: Hemochromatosis: diagnosis and management. Gastroenterology 2001,120:718–725. This paper offers a detailed review of the prevalence of HFE mutations in chronic liver disease and their clinical significance.

    Article  Google Scholar 

  13. Mura C, Raguenes O, Ferec C: HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. Blood 1999, 93:2502–2505.

    PubMed  CAS  Google Scholar 

  14. Tavill AS: Diagnosis and management of hemochromatosis. Hepatology 2001, 33:1321–1328. This paper emphasizes the natural history of the disease as a continuum of stages in which disease progression is not invariable. Phenotypic and genotypic screening measures are analyzed according to disease stage.

    Article  PubMed  CAS  Google Scholar 

  15. Niederau C, Fischer R, Purschel A, et al.: Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996,110:1107–1119.

    Article  Google Scholar 

  16. Ryan E, Byrnes V, Coughlan B, et al.: Underdiagnosis of hereditary hemochromatosis: lack of presentation or penetration? Gut 2002, 51:108–112.

    Article  PubMed  CAS  Google Scholar 

  17. Asberg A, Hveem K, Thorstensen E, et al.: High prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001, 36:1108–1115. A large Norwegian population-based study of 65,328 persons in which phenotypic screening of hereditary hemochromatosis was performed at relatively low cost in combination with a health survey program. The authors also note that the presence of symptoms in affected individuals was similar to that in the general population and that rates of cirrhosis were low.

    Article  PubMed  CAS  Google Scholar 

  18. Waalen J, Felitti V, Gelbart T, et al.: Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. Mayo Clin Proc 2002, 77:522–530.

    Article  PubMed  Google Scholar 

  19. Basset ML, Halliday JW, Powell LW: Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986, 6:24–29.

    Article  Google Scholar 

  20. Olynyk JK, Cullen DJ, Aquilia BA, et al.: A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999, 341:718–724. A population-based study of 3011 individuals of predominantly Anglo-Celtic descent. Conducted over 4 years, it provides longitudinal data on the penetrance of the C282Y mutation. The authors conclude that the majority of C282Y homozygotes develop progressive iron overload; however, only half of these patients had clinical features of hemochromatosis, and 25% had fibrosis or cirrhosis.

    Article  PubMed  CAS  Google Scholar 

  21. Beutler E, Felitti VJ, Koziol JA, et al.: Penetrance of 845G-> A (C282Y) HFE hereditary hemochromatosis mutation in the USA. Lancet 2002, 359:211–218. A study in which 41,038 individuals attending a health appraisal clinic in San Diego were screened for the C282Y and H63D mutations. The authors conclude that penetrance is low on the basis that symptoms in C282Y homozygotes were no more prevalent than in the control population, and that rates of cirrhosis in these patients were less than 1% based on a serologic test for fibrosis.

    Article  PubMed  Google Scholar 

  22. McCune CA, Al-Jader LN, May A, et al.: Hereditary hemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet 2002, 111:538–543.

    Article  PubMed  CAS  Google Scholar 

  23. Crawford DH, Jazwinska EC, Cullen LM, et al.: Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998,114:1003–1008.

    Article  Google Scholar 

  24. Van Vliergerghe H, Langlois M, Delanghe J, et al.: Haptoglobin phenotype 2-2 over-representation in Cys282Tyr hemochromatotic patients. J Hepatol 2001, 35:707–711.

    Article  Google Scholar 

  25. Lee P, Gelbart T, West C, et al.: Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol Dis 2002, 29:471–487.

    Article  PubMed  CAS  Google Scholar 

  26. Carter K, Bowen DJ, McCune CA, et al.: Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical expression in HFE C282Y hemochromatosis: phenotype and genotype analysis. Br J Haematol 2003,122:326–32.

    Article  Google Scholar 

  27. Nicholas G, Bennoun M, Porteu A, et al.: Severe iron deficiency anaemia in transgenic mice expressing liver hepcidin. Proc Natl Acad Sci U S A 2002, 99:4596–4601.

    Article  CAS  Google Scholar 

  28. Nicholas G, Viatte L, Lou DQ, et al.: Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosis. Nat Genet 2003, 34:97–101.

    Article  CAS  Google Scholar 

  29. Nicholas G, Bennoun M, Devaux I, et al.: Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A 2001, 98:8780–8785.

    Article  Google Scholar 

  30. Bridle KR, Frazer DM, Wilkins SJ, et al.: Disrupted hepcidin regulation in HFE-associated hemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 2003, 361:669–673.

    Article  PubMed  CAS  Google Scholar 

  31. Gehrke SG, Kulaksiz H, Hermann T, et al.: Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 2003,102:371–376.

    Article  CAS  Google Scholar 

  32. Fargion S, Valenti L, Dongiovanni P, et al.: Tumour necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001, 97:3707–3712.

    Article  PubMed  CAS  Google Scholar 

  33. Vautier G, Murray M, Olynyk JK: Hereditary hemochromatosis: detection and management. Med J Aust 2001, 175:418–421.

    PubMed  CAS  Google Scholar 

  34. McLaren CE, McLachlan GJ, Halliday JW, et al.: Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology 1998, 114:543–549.

    Article  PubMed  CAS  Google Scholar 

  35. Olynyk JK, Hagan SE, Cullen DJ, et al.: A 17 year study of the evolution of untreated hereditary hemochromatosis in the Busselton Population. Mayo Clin Proc, in press.

  36. Piperno A, Sampietro M, Pietrangelo A, et al.: Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998, 114:996–1002.

    Article  PubMed  CAS  Google Scholar 

  37. Brunt EM, Olynyk JK, Britton RS, et al.: Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am J Gastroenterol 2000, 95:1788–1793.

    PubMed  CAS  Google Scholar 

  38. Guyader D, Jacquelinet C, Moirand R, et al.: Non-invasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998, 115:929–936. An important study in which 197 French C282Y homozygous patients all underwent liver biopsy. The absence of severe hepatic fibrosis was accurately predicted in most patients on the basis of simple clinical and biochemical variables, in particular a ferritin level of less than 1000 ng/mL. A significant proportion of patients with normal AST had severe fibrosis, underlining its lack of utility in predicting liver damage.

    Article  PubMed  CAS  Google Scholar 

  39. Bacon BR, Olynyk JK, Brunt EM, et al.: HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999, 130:953–962. A study in which biopsies of patients with chronic liver disease were obtained and correlated with the HFE genotype. Genotyping enabled more accurate diagnosis of hereditary hemochromatosis among the various forms of liver disease complicated by iron overload.

    PubMed  CAS  Google Scholar 

  40. Olynyk JK, Reddy R, Di Bisceglie AM, et al.: Hepatic iron concentration as a predictor of response to alpha interferon therapy in chronic hepatitis C. Gastroenterology 1995, 108:1104–1109.

    Article  PubMed  CAS  Google Scholar 

  41. Bataller R, North KE, Brenner DA.: Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003, 37:493–503.

    Article  PubMed  CAS  Google Scholar 

  42. Chitturi S, Weltman M, Farrell GC, et al.: HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002, 36:142–149.

    Article  PubMed  CAS  Google Scholar 

  43. George DK, Goldwurm S, Macdonald GA, et al.: Increased hepatic iron concentration in non-alcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114:311–318.

    Article  PubMed  CAS  Google Scholar 

  44. Ellervik C, Mandrup-Poulsen T, Nordestgaard BG, et al.:Prevalence of hereditary hemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet 2001, 358:1405–1409.

    Article  PubMed  CAS  Google Scholar 

  45. Phelps G, Chapman I, Hall P, et al.: Prevalence of genetic hemochromatosis among diabetic patients. Lancet 1989, 2:233–234.

    Article  PubMed  CAS  Google Scholar 

  46. Olynyk J, Hall P, Ahern M, et al.: The prevalence of genetic hemochromatosis in patients with peripheral arthritis. Aust NZ J Med 1994, 24:22–25.

    CAS  Google Scholar 

  47. Willis G, Scott DG, Jennings BA, et al.: HFE mutations in an inflammatory arthritis population. Rheumatology 2002, 41:176–179.

    Article  PubMed  CAS  Google Scholar 

  48. Timms AE, Sathananthan R, Bradbury L, et al.: Genetic testing for hemochromatosis in patients with chondrocalcinosis. Ann Rheum Dis 2003, 61:745–747.

    Article  Google Scholar 

  49. Krawczak M, Cooper DN, Schmidtke J: Estimating the efficacy and efficiency of cascade genetic screening. Am J Hum Genet 2001, 69:361–370.

    Article  PubMed  CAS  Google Scholar 

  50. Adams PC, Speechley M, Kertesz AE: Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991, 101:368–372.

    PubMed  CAS  Google Scholar 

  51. Hickman PE, Hourigan LF, Powell LW, et al.: Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous hemochromatosis. Gut 2000, 46:405–409.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital Campus, PO Box 480, 6959, Fremantle, Western Australia

    Sumedha P. Galhenage MBBS, Charlie H. Viiala MBBS, FRACP & John K. Olynyk MD, FRACP

Authors
  1. Sumedha P. Galhenage MBBS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charlie H. Viiala MBBS, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John K. Olynyk MD, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Galhenage, S.P., Viiala, C.H. & Olynyk, J.K. Screening for hemochromatosis: Patients with liver disease, families, and populations. Curr Gastroenterol Rep 6, 44–51 (2004). https://doi.org/10.1007/s11894-004-0025-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11894-004-0025-2

Keywords

Search

Navigation